By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug is to be ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...